ALLUVI: A DEEP EXPLORATION INTO THE DRUG'S POTENTIAL

Alluvi, formerly LY3414901, represents a exciting advancement in metabolic management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist shows remarkable efficacy in early trial data, with substantial weight loss observed in